|
[1] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132.
|
|
[2] LIU X, GUO XZ. Early diagnosis of pancreatic cancer[J]. J Clin Hepatol, 2016, 32 (5) :864-866. (in Chinese) 刘旭, 郭晓钟.胰腺癌的早期诊断[J].临床肝胆病杂志, 2016, 32 (5) :864-866.
|
|
[3] ZHU LN, LIN F, SHANG ZN, et al. Mechanism of action of recombinant interleukin-2 combined with allicin in treatment of pancreatic cancer[J]. J Clin Hepatol, 2016, 32 (10) :1943-1946. (in Chinese) 朱立宁, 林峰, 商振宁, 等.重组IL-2联合大蒜素治疗胰腺癌的作用机制[J].临床肝胆病杂志, 2016, 32 (10) :1943-1946.
|
|
[4] MATSUMOTO G, NAGAI S, MUTA M, et al. Survival benefit of KRN7000 immune therapy in combination with TNP470 in hamster liver metastasis model of pancreatic cancer[J]. Oncol Rep, 2003, 10 (5) :1201-1206.
|
|
[5] WOLPIN BM, O'REILLY EM, KO YJ, et al. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer[J]. Ann Oncol, 2013, 24 (7) :1792-1801.
|
|
[6] VONDERHEIDE R, BAJOR D, WINOGRAD R, et al. CD40 immunotherapy for pancreatic cancer[J]. Cancer Immunol Immunother, 2013, 62 (5) :949-954.
|
|
[7] BEATTY GL, CHIOREAN EG, FISHMAN MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans[J]. Science, 2011, 331 (6024) :1612-1616.
|
|
[8] XU BB, HE YJ, WANG WL, et al. Research progress of immune checkpoint therapy for cancer[J]. Chin J Clin Pharmacol Ther, 2016, 21 (2) :218-224. (in Chinese) 许标波, 贺毅憬, 王韦力, 等.肿瘤免疫检查点抑制剂临床治疗的研究进展[J].中国临床药理学与治疗学, 2016, 21 (2) :218-224.
|
|
[9] ROYAL R, LEVY C, TURNER K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma[J]. J Immunother, 2010, 33 (8) :828-833.
|
|
[10] LE D, LUTZ E, URAM J, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer[J]. J Immunother, 2013, 36 (7) :382-389.
|
|
[11] AGLIETTA M, BARONE C, SAWYER MB, et al. A phase I dose escalation trial of tremelimumab (CP-675, 206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer[J]. Ann Oncol, 2014, 25 (9) :1750-1755.
|
|
[12] BRAHMER JR, TYKODI SS, CHOW LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366 (26) :2455-2465.
|
|
[13] SOARES K, RUCKI A, WU A, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors[J]. J Immunother, 2015, 38 (1) :1-11.
|
|
[14] WINOGRAD R, BYRNE KT, EVANS RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma[J]. Cancer Immunol Res, 2015, 3 (4) :399-411.
|
|
[15] VONDERHEIDE RH. CD47 blockade as another immune checkpoint therapy for cancer[J]. Nat Med, 2015, 21 (10) :1122.
|
|
[16] MICHAELS AD, NEWHOOK TE, ADAIR SJ, et al. CD47 blockade as an adjuvant immunotherapy for resectable pancreatic cancer[J]. Clin Cancer Res, 2018, 24 (6) :1415-1425.
|
|
[17] GOLUBOVSKAYA V, BERAHOVICH R, ZHOU H, et al. CD47-CAR-T cells effectively kill target cancer cells and block pancreatic tumor growth[J]. Cancers, 2017, 9 (10) :139.
|
|
[18] IBRAHIM AM, WANG YH. Viro-immune therapy:A new strategy for treatment of pancreatic cancer[J]. World J Gastroenterol, 2016, 22 (2) :748-763.
|
|
[19] WANG M, SHI SB, QI JL, et al. S-1 plus CIK as second-line treatment for advanced pancreatic cancer[J]. Med Oncol, 2013, 30 (4) :747.
|
|
[20] CHUNG M, PARK J, BANG S, et al. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer[J]. Cancer Immunol Immunother, 2014, 63 (9) :939-946.
|
|
[21] JIANG N, QIAO G, WANG X, et al. Dendritic cell/cytokine-induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer:A prospective study[J]. Clin Cancer Res, 2017, 23 (17) :5066-5073.
|
|
[22] LIU AF, XIN LY, ZHONG SS, et al. Research progress on chimeric antigen receptor T-cell in hematological malignacies[J]. Chin J Cancer Prev Treat, 2016, 23 (19) :1333-1338. (in Chinese) 刘爱飞, 辛柳燕, 钟思思, 等.嵌合抗原受体型T淋巴细胞在血液肿瘤中的研究进展[J].中华肿瘤防治杂志, 2016, 23 (19) :1333-1338.
|
|
[23] DESELM CJ, TANO ZE, VARGHESE AM, et al. CAR T-cell therapy for pancreatic cancer[J]. J Surg Oncol, 2017, 116 (1) :63-74.
|
|
[24] CHMIELEWSKI M, HAHN O, RAPPL G, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice[J]. Gastroenterology, 2012, 143 (4) :1095-1107.
|
|
[25] JIANG H, SONG B, WANG P, et al. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells[J]. Protein Cell, 2017, 8 (12) :926-931.
|
|
[26] BEATTY GL, O'HARA MH, LACEY SF, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial[J]. Gastroenterology, 2018, 155 (1) :29-32.
|
|
[27] MOHAMMED S, SUKUMARAN S, BAJGAIN P, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer[J]. Mol Ther, 2017, 25 (1) :249-258.
|
|
[28] BATCHU RB, GRUZDYN OV, MAHMUD EM, et al. Inhibition of interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro[J]. Surgery, 2018, 163 (3) :627-632.
|
|
[29] MASUYAMA J, MURAKAMI T, IWAMOTO S, et al. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies[J]. Cytotherapy, 2016, 18 (1) :80-90.
|
|
[30] LIN M, ALNAGGAR M, LIANG S, et al. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer[J].Oncotarget, 2017, 8 (60) :101795-101807.
|
|
[31] LIN M, LIANG S, WANG X, et al. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer:A promising treatment[J]. J Cancer Res Clin Oncol, 2017, 143 (12) :2607-2618.
|
|
[32] COVELER A, ROSSI G, VAHANIAN N, et al. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma[J]. Immunotherapy, 2016, 8 (2) :117-125.
|
|
[33] HARDACRE JM, MULCAHY M, SMALL W, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer:A phase 2 study[J]. J Gastrointest Surg, 2013, 17 (1) :94-100.
|
|
[34] LUTZ E, YEO CJ, LILLEMOE KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation[J]. Ann Surg, 2011, 253 (2) :328-335.
|
|
[35] LAHERU D, LUTZ E, BURKE J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer:A pilot study of safety, feasibility, and immune activation[J]. Clin Cancer Res, 2008, 14 (5) :1455-1463.
|
|
[36] GJERTSEN MK, BUANES T, ROSSELAND AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colonystimulating factor as adjuvant:Clinical and immunological responses in patients with pancreatic adenocarcinoma[J]. Int J Cancer, 2001, 92 (3) :441-450.
|
|
[37] ABOU-ALFA GK, CHAPMAN PB, FEILCHENFELDT J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine[J]. Am J Clin Oncol, 2011, 34 (3) :321-325.
|
|
[38] VAKOC CR, TUVESON DA. Untangling the genetics from the epigenetics in pancreatic cancer metastasis[J]. Nat Genet, 2017, 49 (3) :323-324.
|
|
[39] BERNHARDT SL, GJERTSEN MK, TRACHSEL S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer:A dose escalating phase I/II study[J]. Br J Cancer, 2006, 95 (11) :1474-1482.
|
|
[40] STAFF C, MOZAFFARI F, FRODIN JE, et al. Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients[J]. Int J Oncol, 2014, 45 (3) :1293-1303.
|
|
[41] MIDDLETON G, SILCOCKS P, COX T, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac) :An open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2014, 15 (8) :829-840.
|
|
[42] SHANG N, FIGINI M, SHANGGUAN J, et al. Dendritic cells based immunotherapy[J]. Am J Cancer Res, 2017, 7 (10) :2091-2102.
|
|
[43] GHANSAH T, VOHRA N, KINNEY K, et al. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma[J]. Cancer Immunol Immunother, 2013, 62 (6) :1083-1091.
|
|
[44] SHINDO Y, HAZAMA S, MAEDA Y, et al. Adoptive immunotherapy with MUC1-m RNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer[J]. J Transl Med, 2014, 12:175.
|
|
[45] COSTA NEVES M, GIAKOUSTIDIS A, STAMP G, et al. Extended survival after complete pathological response in metastatic pancreatic ductal adenocarcinoma following induction chemotherapy, chemoradiotherapy, and a novel immunotherapy agent, IMM-101[J].Cureus, 2015, 7 (12) :e435.
|
|
[46] DALGLEISH AG. Long term survival in IMAGE 1 (immune modulation and gemcitabine evaluation 1) , a randomized, open-label phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer[J]. J Clin Oncol, 2015, 33 (Suppl15) :3051.
|
|
[47] LE DT, BROCKSTEDT DG, NIR-PAZ R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers:Phase I studies of safety and immune induction[J]. Clin Cancer Res, 2012, 18 (3) :858-868.
|
|
[48] LE DT, WANG-GILLAM A, PICOZZI V, et al. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33 (12) :1325-1333.
|
DownLoad: